2017 Annual Meeting | C229 - Emerging Therapies in Epilepsy

Date Friday 04/28/17

Time 07:00 AM - 09:00 AM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Daniel Friedman, MD

Topic(s)

Learning Objectives Participants should be able to have greater understanding of the current evidence to support the safety and efficacy of various cannabinoids for epilepsy treatment as well as potential interactions with anti-seizure drugs. Participants will also become familiar with new approaches to surgical treatment of epilepsy including laser ablation, stereotactic radiosurgery, and ultrasound-based therapies; learn about the evidence supporting these new modalities and which patients may be appropriate these new options; and understand new treatments for status epilepticus, including out-of-hospital therapies and strategies for management of refractory status epilepticus.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Advanced Practice Provider

Teaching Styles Didactic, Interactive, Audience Participation

Event Timeline
07:00 AM - 07:05 AM	Luncheon	Introduction Daniel Friedman, MD
07:05 AM - 07:35 AM	Speaker	Update on Cannabinoids for Epilepsy Daniel Friedman, MD
07:35 AM - 07:45 AM	Q&A	Questions and Answers Daniel Friedman, MD
07:45 AM - 08:15 AM	Speaker	Minimally and Non-invasive Surgical Treatments for Focal Epilepsy Jerry J. Shih, MD, FAAN
08:15 AM - 08:25 AM	Q&A	Questions and Answers Jerry J. Shih, MD, FAAN
08:25 AM - 08:55 AM	Speaker	New and Emerging Treatments for Status Epilepticus John Betjemann, MD
08:55 AM - 09:00 AM	Q&A	Questions and Answers John Betjemann, MD

Faculty Disclosures
Daniel Friedman, MD	The institution of Dr. Friedman has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Epilepsy Study Consortium (non-profit). Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Meili Technology. Dr. Friedman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis. Dr. Friedman has stock in Neuroview Technology. The institution of Dr. Friedman has received research support from NIH. The institution of Dr. Friedman has received research support from CDC. The institution of Dr. Friedman has received research support from Epitel. The institution of Dr. Friedman has received research support from Neuropace. Dr. Friedman has received intellectual property interests from a discovery or technology relating to health care. Dr. Friedman has received intellectual property interests from a discovery or technology relating to health care. Dr. Friedman has received publishing royalties from a publication relating to health care. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Speaker Honorarium with SK Life Sciences. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Speaker Honorarium with AAN. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Travel Reimbursement with Epilepsy Foundation of America.
Jerry J. Shih, MD, FAAN	Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurelis. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SK Life. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovion. The institution of Dr. Shih has received research support from Neurona. The institution of Dr. Shih has received research support from NCGS, Inc. Dr. Shih has a non-compensated relationship as a Test Writing Committee Member with ABPN that is relevant to AAN interests or activities.
John Betjemann, MD	No disclosure on file

��ɫ��

��ɫ��